Monte Rosa Therapeutics (GLUE) EBT (2020 - 2026)

Monte Rosa Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$44.5 million for Q1 2026.

• In Q1 2026, EBT fell 193.18% year-over-year to -$44.5 million; the TTM figure through Mar 2026 stood at -$115.2 million (down 1317.87% YoY), while the FY2025 annual figure was -$23.1 million, up 67.09% from the prior year.
• EBT for Q1 2026 stood at -$44.5 million, down from -$29.4 million in the prior quarter.
• The five-year high for EBT was $47.7 million in Q1 2025, with the low at -$64.8 million in Q1 2022.
• The 5-year median for EBT is -$30.3 million (2025), against an average of -$24.8 million.
• The sharpest annual moves came in 2022 and 2025: EBT plunged 463.48% in 2022, then surged 249.62% in 2025.
• Monte Rosa Therapeutics' EBT stood at -$30.8 million in 2022, then slipped by 8.1% to -$33.3 million in 2023, then jumped by 146.89% to $15.6 million in 2024, then sank by 288.64% to -$29.4 million in 2025, then plunged by 51.04% to -$44.5 million in 2026.
• Business Quant data shows GLUE's EBT at -$44.5 million in Q1 2026, -$29.4 million in Q4 2025, and -$30.3 million in Q3 2025.